EPRX Eupraxia Pharmaceuticals Inc.
Company Analysis
Latest News
Eupraxia Hits 120-Patient Enrollment Target in RESOLVE Phase 2b Trial
Eupraxia Pharmaceuticals Inc. reached its enrollment target for the placebo-controlled Phase 2b portion of its RESOLVE trial of EP-104GI, an investigational...
🔴 Eupraxia Pharmaceuticals is trading 5% down as no company-specific catalyst is confirmed
Eupraxia Pharmaceuticals is trading at $6.93, down 5.26%, with healthcare-sector weakness a possible contributor. - XLV fell 1.37% during the regular session...
🟢 Eupraxia Pharmaceuticals is trading 7% up in pre-market — no confirmed catalyst identified
Eupraxia Pharmaceuticals is trading at $7.99, up 7.07%, in pre-market; no confirmed catalyst for the move has been identified. - The company is scheduled to...
🟢 Eupraxia Pharmaceuticals is trading 7.1% up in after-hours trading with no confirmed catalyst
Eupraxia Pharmaceuticals is trading at $7.99, up 7.10%, with no specific after-hours catalyst established. - On October 9, Eupraxia Pharmaceuticals announced...
Eupraxia Draws Cantor's $19 Target Reaffirmation, With Over 140% Upside
On October 8, 2026, Cantor Fitzgerald reiterated its Overweight rating on Eupraxia Pharmaceuticals (NASDAQ: EPRX). The firm maintained its $19.00 price target....
🟢 Eupraxia Pharmaceuticals is trading 5.9% up in pre-market
Eupraxia Pharmaceuticals is trading 5.94% up at $8.02 in pre-market; no new company-specific announcement explains the October 9 move. - The October 8 close...
🔴 Eupraxia Pharmaceuticals is trading 5.66% down today amid oil and Treasury-yield concerns
Eupraxia Pharmaceuticals is trading 5.66% down at $7.34 with the market open amid broader oil-price and Treasury-yield concerns. - No clear company-specific...
🔴 Eupraxia Pharmaceuticals is trading 9.9% down in pre-market
Eupraxia Pharmaceuticals is trading 9.9% down at $7.01, with no clear company-specific announcement identified for October 8. - The latest surfaced company...
🟢 Eupraxia Pharmaceuticals is trading 19.4% up in pre-market
Eupraxia Pharmaceuticals is trading 19.4% higher at $9.25 in pre-market on October 6, 2026; no company announcement is listed for October 5 or 6. - Shares...
🟢 Eupraxia Pharmaceuticals is trading 9.75% up in pre-market
Eupraxia Pharmaceuticals is trading at $8.50, up 9.75% in pre-market, with no clear company-specific catalyst identified. - Its latest release, dated...
🟢 Eupraxia Pharmaceuticals is trading 5% up with no clear catalyst identified
Eupraxia Pharmaceuticals is trading at $7.61, up 5.11%, with no clear company-specific catalyst identified for October 5. - The latest listed release is...
🔴 Eupraxia Pharmaceuticals is trading 5% down; no clear catalyst identified
Eupraxia Pharmaceuticals is trading at $7.42, down 5.24%, with no clear company-specific catalyst identified for October 2. - The shares were also down 13.96%...
🔴 Eupraxia Pharmaceuticals is trading 11% down today with no clear company-specific catalyst reported
Eupraxia Pharmaceuticals is trading 10.99% down at $8.10, with no clear company-specific news reported on October 1 explaining the decline. - Shares rose...
🔴 Eupraxia Pharmaceuticals is trading 6.3% down
Eupraxia Pharmaceuticals is trading at $8.53, down 6.32%; reporting identifies no new company-specific catalyst. - On September 30, shares rose 9.57% to $9.10...
Eupraxia's One-Shot EoE Drug Holds Patients in Remission for a Year — But Can a 14-Patient Trial Justify a $600 Million Bet?
Shares of Eupraxia Pharmaceuticals surged 10.6% to $9.19 after the clinical-stage biotech reported that a single dose of its swallowed steroid capsule kept 64%...
🟢 Eupraxia Pharmaceuticals is trading 10.63% up today after 64% remained in remission at 52 weeks
Eupraxia Pharmaceuticals is trading 10.63% up at $9.19; the clearest catalyst is its September 30 RESOLVE trial report. - In Phase 1b/2a, 9 of 14 patients...
🟢 Eupraxia Pharmaceuticals is trading 5.48% up today amid 52-week clinical remission results
Eupraxia Pharmaceuticals is trading 5.48% higher at $8.76, amid company-reported Phase 1b/2a RESOLVE trial results. - On September 30, 2026, 64% (9 of 14)...
🟢 Eupraxia Pharmaceuticals is trading 6% up in pre-market
Eupraxia Pharmaceuticals is trading at $8.49, up 5.99% in pre-market; no company-specific announcement explaining the September 28 gain was identified. - The...
Two Wall Street Firms Bet Big on Eupraxia's Throat Treatment — But Can a $9 Stock Really Be Worth $25?
Shares of Eupraxia Pharmaceuticals surged 10.6% to $9.00 on September 24 after two analyst upgrades converged on the same thesis: the company's experimental...
🟢 Eupraxia Pharmaceuticals is trading 11% up in pre-market after Stifel reiterated Buy ahead of interim data
Eupraxia Pharmaceuticals is trading 10.57% higher at $9.00 after Stifel reiterated a Buy rating and $25.00 price target on September 24, 2026, ahead of interim...